Clinical Research Directory
Browse clinical research sites, groups, and studies.
Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
Sponsor: Region Skane
Summary
Two commonly used treatments for latent tuberculosis infection are either 4 months rifampicin or 6-9 months isoniazid. The invistigators will study the risk of acquisition of rifampicin resistance in commensal Staphylococcus aureus in persons treated with rifampicin versus in persons treated with isoniazide. Through repeated swab cultures before, during, and after treatment the investigators will also investigate potential accumulation of mutations associated with rifampicin resistance over time. Finally, household contacts to persons with rifampicin-resistant S. aureus will be examined to investigate whether onward transmission of rifampicin-resistant S. aureus occurs within households.
Official title: Acquisition and Persistence of Rifampicin Resistance in Staphylococcus Aureus During and After Treatment for Latent Tuberculosis
Key Details
Gender
All
Age Range
16 Years - Any
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2021-09-30
Completion Date
2026-12
Last Updated
2024-07-15
Healthy Volunteers
No
Conditions
Interventions
No intervention is part of the study protocol
No intervention is part of the study protocol. The choice of treatment for latent tuberculosis is is made by the treating physician.
Locations (1)
Skåne University Hospital
Malmo, Sweden